Overview

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine to what extend a treatment with the iron compounds Iron Isomaltoside 1000 or Ferric Carboxymaltose is leading to hypophosphatemia and to study the potential clinical impact of hypophosphatemia.
Phase:
Phase 4
Details
Lead Sponsor:
Saarland University
Universität des Saarlandes
Treatments:
Ferric Compounds
Iron
Iron isomaltoside 1000